Regarding regional nodal irradiation for triple positive breast cancers, how much do you weigh in the availability of effective adjuvant systemic therapies (i.e, hormonal and anti-Her2 therapy) in theory being able to control subclinical nodal disease without the need for RT consolidation?

Some of these questions are unanswered, as systemic therapy has changed for the subset of breast cancer who are suitable for targeted therapy. That being said, with improved systemic treatment, the absolute benefit of RT may be small but this improved locoregional control may have a higher impact on...